

1 **Emergence of SARS-CoV-2 variant B.1.575.2 containing the E484K**
2 **mutation in the spike protein in Pamplona (Spain) May-June 2021**

3 **Running title: Emergence of B.1.575.2 SARS-CoV-2 lineage in Pamplona (Spain)**

4 Camino Trobajo-Sanmartín^{1,2*}, Ana Miqueleiz^{1,2}, María Eugenia Portillo^{1,2}, Miguel

5 Fernández-Huerta^{1,2}, Ana Navascués^{1,2}, Pilar Sola Sara³, Paula López Moreno³,

6 Gonzalo R Ordoñez⁴, Jesús Castilla^{2,5,6}, Carmen Ezpeleta^{1,2}

7 ¹Departament of Clinical Microbiology, Complejo Hospitalario de Navarra. Pamplona,
8 Spain.

9 ² Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

10 ³ Servicio de Urgencias Extrahospitalarias (SUE), Pamplona, Spain

11 ⁴ Centro de Secuenciación NASERTIC, Pamplona, Spain.

12 ⁵ Instituto de Salud Pública de Navarra, Pamplona, Spain.

13 ⁶ CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

14 *Corresponding author: Camino Trobajo-Sanmartín

15 Email: camino.trobajo.sanmartin@navarra.es

16 **Keywords:** SARS-CoV-2, E484K mutation, lineage B.1.575, variant, sequencing

17

18 **Abstract**

19 With the emergence of new SARS-CoV-2 variants and the acquisition of novel
20 mutations in exiting lineages, the need to implement methods capable of monitoring
21 viral dynamics arises. We report the emergence and spread of a new SARS-CoV-2
22 variant within B.1.575 lineage containing the E484K mutation in the spike protein
23 (named B.1.575.2) in a region of Northern Spain between May and June 2021.
24 SARS-CoV-2 positive samples with cycle threshold value less than or equal to 30 were
25 selected to screen of presumptive variants using the TaqPath™ COVID-19 RT-PCR kit
26 and TaqMan™ SARS-CoV-2 Mutation Panel. Confirmation of variants was performed
27 by whole genome sequencing. Of the 200 samples belonging to the B.1.575 lineage, 194
28 (97%) corresponded to the B.1.575.2 sub-lineage, which was related to the presence of
29 the E484K mutation. Of 197 cases registered in GISAID EpiCoV database as lineage
30 B.1.575.2 194 (99.5%) were identified in Pamplona (Spain).
31 This report emphasizes the importance of complementing surveillance of SARS-CoV-2
32 with sequencing for the rapid control of emerging viral variants.

33

34 **Introduction**

35 During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic,
36 several variants were catalogued as variants of concern (VOC) and variants of interest
37 (VOI) by the European Centre for Disease Prevention and Control has emerged in
38 different countries. As of June 23, 2021, the four important lineages with evidenced
39 impact on transmissibility, severity and immunity are lineage B.1.1.7 (Alpha), B.1.351
40 (Beta), B.1.617.2 (Delta), and P.1 (Gamma) (1-4). Lineages B.1.351 and P.1 were of
41 specific concern because they present the spike mutation E484K, which has been
42 associated with the reduced neutralizing activity of antibodies and may be associated

43 with the reduced efficacy of the vaccine (2,3,5,6). Initially, the B.1.1.7 lineage had
44 mutations N501Y and D614G and the characteristic Δ H69/ Δ V70 deletion in the spike
45 protein; however, in early 2021, Public Health England reported the first B.1.1.7 SARS-
46 CoV-2 cases that had acquired the E484K mutation (3,7).

47 In this regard, concerns about the emergence of new SARS-CoV-2 variants and the
48 acquisition of new mutations in existing lineages, such as the accumulation of mutations
49 in the spike gene in B.1.1.7, have been developing since the onset of the pandemic.

50 This study identified the emergence and spread of the E484K spike mutation within the
51 SARS-CoV-2 B.1.575 lineage that has increased in the circulating virus population in
52 Pamplona (Spain) between May and June 2021. Additionally, we share our experience
53 with the prospective surveillance of novel SARS-CoV-2 variants by implementing a
54 two-step laboratory strategy: reverse transcription quantitative real-time polymerase
55 chain reaction PCR (RT-qPCR) screening and whole genome sequencing.

56 **Materials and methods**

57 The Microbiology Department of the Complejo Hospitalario de Navarra, located in
58 Pamplona, the capital city of Navarra (Spain), is the reference laboratory of the public
59 health system for SARS-CoV-2 (approximately 650,000 inhabitants). Upper respiratory
60 specimens for SARS-CoV-2 detection are routinely collected at the hospital and
61 primary care centers, and processed by commercial RT-qPCR methods. Since the end of
62 2020, when variant B.1.1.7 became predominant in the United Kingdom, prospective
63 sample-based surveillance has been conducted in our community to identify novel
64 emerging SARS-CoV-2 variants. A two-step laboratory procedure included all positive
65 SARS-CoV-2 samples from hospital patients and community settings with a cycle
66 threshold (Ct) less or equal to 30. Occasionally, targeted samples are also included
67 according to epidemiological criteria.

68 Screening of presumptive SARS-CoV-2 variants carrying Δ H69- Δ V70 deletion was
69 performed using the TaqPath™ COVID-19 RT-PCR kit (Thermo Fisher Scientific,
70 USA) following the manufacturer's instructions. Then, all those samples non-B.1.1.7
71 variants were subjected to a second RT-qPCR, TaqMan™ SARS-CoV-2 Mutation
72 Panel (Thermo Fisher Scientific, USA). At that moment, we customized TaqMan assay
73 for detecting SARS-CoV-2 spike protein with the N501Y, E484K, K417N, K417T
74 mutations. All samples were sequenced.

75 Whole-genome sequencing was performed using Illumina COVIDSeq Test (Illumina
76 Inc, USA) on the Illumina NovaSeq 6000 located in the public company NASERTIC,
77 following the manufacturer's instructions. The viral lineages classifications were
78 performed by the Global Initiative on Sharing Avian Influenza Data (GISAID)
79 (<https://www.gisaid.org/>) [GISAID EpiCoV] database, Nextstrain
80 (<https://nextstrain.org/>) [Nextstrain] and Phylogenetic Assignment of Named Global
81 Outbreak (PANGO) Lineages (<https://cov-lineages.org/>) [Pango] (8-10).

82 **Results**

83 As of August 1, 2021, a total of 4,728 SARS-COV-2 genomes have been sequenced in
84 Navarra. Our sequencing analysis of the SARS-CoV-2 identified 200 (4.2%) samples
85 related to the B.1.575 lineage: four (2%) B.1.575, two (1%) B.1.575.1 and 194 (97%)
86 B.1.575.2. Among the common substitutions present in these lineages, four occurred in
87 the spike protein (S494P, D614G, P681H, T716I). (11). All samples showed a gene S
88 positive (not carrying Δ H69- Δ V70 deletion) in TaqPath. In TaqMan, all samples
89 identified by sequencing as B.1.575.2 showed the E484K mutation.

90 The first case with B.1.575 lineage to be identified in Pamplona dates back to January
91 20, 2021; since that date, no other case was identified until March 15, 2021, where three
92 isolates showing mutations common to the B.1.575 lineage were recorded.

93 Between weeks 20 to 26 2021, we identified 194 cases with lineage B.1.575, which had
94 acquired another S mutation, E484K, classified in the GISAID EpiCoV and Pangolin
95 databases as the sub-lineage B.1.575.2. The first case with B.1.575.2 lineage was
96 identified in a sample isolated on May 19 (week 20, 2021), and the number of cases
97 grew up to 48 cases in weeks 23 and 24 and declined therefore (Figure 1). The
98 beginning of the outbreak was detected in a car repair shop located in a district of
99 Pamplona. These cases could be related to another more significant outbreak of variant
100 B.1.575.2, which was found in a mosque. Since these first cases, the variant has spread
101 throughout Pamplona and its surroundings without affecting the rest of Navarra. The
102 median age of patients was 33 ± 17 years old, 46.2% women, 53.8% men and
103 approximately 50% Arab origin. Eighty-two (43.1%) patients acquired the infection at
104 domiciliary ambit, the most common cause. Only 14 (7.1%) acquired it at the
105 workplace. One hundred and fifty-six (79.7%) patients showed symptoms, and only
106 four (2.2%) were admitted to hospitals, but none was a severe case. Six (3.3%) of
107 patients have been fully vaccinated for COVID-19 and 35 (19.2%) had received any
108 vaccine dose.

109 To know the distribution of SARS-CoV-2 B.1.575 lineage, we searched in the GISAID
110 EpiCoV and PANGO lineages databases. From May to July, the lineage and sub-
111 lineages of B.1.575 have increased exponentially in different countries. The B.1.575
112 lineage was predominant in the United States of America (USA) (90%), while the
113 B.1.575.1 and B.1.575.2 sub-lineages dominated Spain with 86% and 92%,
114 respectively.

115 The B.1.575.2 sub-lineage was predominant in Navarra since 99.5% (194/197) of the
116 cases registered in the GISAID EpiCoV database were identified in this region. By

117 contrast, we did not identify any genomes with B.1.575 and B.1.575.1 lineage carrying
118 the E484K mutation.

119 **Conclusions**

120 In this study, we observed the emergence of a lineage B.1.575.2 to acquire the spike
121 E484K mutation circulating in Pamplona associated an outbreak. The new lineage
122 displayed a low prevalence (4.10%) among SARS-CoV-2 genomes analyzed between
123 March 23, 2020, and June 30, 2021. Still, it is already dispersed in our city and
124 comprises 97% of the B.1.575 sequences detected in that period. The E484K mutation
125 is considered one of the most important substitutions associated with reduced antibody
126 neutralization potency and efficacy of the SARS-CoV-2 vaccine (12-14). The E484K
127 mutation has been identified in SARS-CoV-2 variants considered VOC such as B.1.351,
128 P.1 and B.1.1.7+E484K and in VOI variants such as B.1.525, B.1.620, and B1.621
129 among others (1-3), so the presence of this mutation should be supervised and
130 monitored.

131 Screening PCR is a useful tool for detecting mutations, mainly because of its rapidity.
132 Future identifications with this method could include new mutations characteristic of
133 the lineage could serve as a rapid method of variant identification. However, whole
134 genome sequencing remains the gold standard technique for pandemic control.

135 This brief report emphasizes the importance of exhaustive surveillance for circulating
136 variants of the SARS-CoV-2 virus to reduce community transmission and prevent the
137 emergence of more transmissible variants that could further increase the severity of the
138 epidemic in the country.

139 **Conflict of interest**

140 The authors declare no conflict of interest.

141 **Funding**

142 This work was supported by the Horizon 2020 program of the European Commission (I-
143 MOVE-COVID-19, grant agreement No 101003673) and the Carlos III Institute of
144 Health with the European Regional Development Fund (COV20/00542).

145 **Acknowledgements**

146 We would like to thank the GISAID EpiCoV database and all contributing researchers
147 for making the genomes publicly available.

148 **Access to data**

149 All genomes generated in this work were deposited in the GISAID EpiCoV database
150 (<http://gisaid.org>).

151 **Author contributions**

152 CTS, AM, MEP, MFH AN, CE conceived and designed the study. GRO was
153 responsible for the whole genome sequencing interpretation. PSS, PLM, JC provided
154 epidemiology data. CTS wrote the manuscript, and all authors critically revised the
155 manuscript. All authors approved the final version of the manuscript and were
156 accountable for its accuracy.

157

158

159 **References**

- 160 1. CDC: Available from: <https://www.cdc.gov/coronavirus/2019-ncov/cases->
161 [updates/variant-surveillance/variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html). Accessed 30 June 2021.
- 162 2. Hirotsu Y, Omata M. 2021. Detection of R.1 lineage severe acute respiratory
163 syndrome coronavirus 2 (SARS-CoV-2) with spike protein
164 W152L/E484K/G769V mutations in Japan. *PLoS Pathog*;17:e1009619.
165 <http://doi.org/10.1371/journal.ppat.1009619>.
- 166 3. Moustafa AM, Bianco C, Denu L, Ahmed A, Neide B, Everett J, Reddy S,
167 Rabut E, Deseignora J, Feldman MD, Rodino KG, Bushman F, Harris RM, Mell
168 JC, Planet PJ. Comparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2
169 isolates from Pennsylvania. Preprint. *bioRxiv* 2021;2021.04.440801.
170 <http://doi.org/10.1101/2021.04.21.440801>.
- 171 4. European Centre for Disease Prevention and Control. Implications for the
172 EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of
173 concern-23 June 2021. ECDC: Stockholm; 2021.
- 174 5. Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H,
175 Errico JM, Theel ES, Liebeskind MJ, Alford B, Buchser WJ, Ellebedy AH,
176 Fremont DH, Diamond MS, Whelan SPJ. 2021. Identification of SARS-CoV-2
177 spike mutations that attenuate monoclonal and serum antibody neutralization.
178 *Cell Host Microbe* 29:477–488. <http://doi.org/10.1016/j.chom.2021.01.014>.
- 179 6. Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts
180 T, Bennett H, Boyoglu-Barnum S, Shi W, Moliva JI, Sullivan NJ, Graham BS,
181 Carfi A, Corbett KS, Seder RA, Edwards DK. 2021. Serum Neutralizing
182 Activity Elicited by mRNA-1273 Vaccine. *N Engl J Med* 384:1468–1470.
183 <http://doi.org/10.1056/NEJMc2102179>.
- 184 7. Public Health England. Investigation of novel SARS-CoV-2 variant: Variant of
185 Concern 202012/01 (Technical briefing 5). 2021.
186 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/atta](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf)
187 [chment_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical Bri](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf)
188 [efing_5.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf).
- 189 8. Shu Y, McCauley J. 2017. GISAID: Global initiative on sharing all influenza
190 data from vision to reality. *Euro Surveill* 22:30494.
191 <https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494>.

- 192 9. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko
193 P, Bedford T, Neher RA. 2018. Nextstrain: real-time tracking of pathogen
194 evolution. *Bioinformatics* 34:4121–4123.
195 <https://doi.org/10.1093/bioinformatics/bty407>.
- 196 10. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, du Plessis L,
197 Pybus OG. 2020. A dynamic nomenclature proposal for SARS-CoV-2 lineages
198 to assist genomic epidemiology. *Nat Microbiol* 5:1403–1407.
199 <https://doi.org/10.1038/s41564-020-0770-5>.
- 200 11. B.1.575 Lineage Report. Alaa Abdel Latif, Julia L. Mullen, Manar Alkuzweny,
201 Ginger Tsueng, Marco Cano, Emily Haag, Jerry Zhou, Mark Zeller, Emory
202 Hufbauer, Nate Matteson, Chunlei Wu, Kristian G. Andersen, Andrew I. Su,
203 Karthik Gangavarapu, Laura D. Hughes, and the Center for Viral Systems
204 Biology. outbreak.info, (available at [https://outbreak.info/situation-](https://outbreak.info/situation-reports?pango=b.1.575)
205 [reports?pango=b.1.575](https://outbreak.info/situation-reports?pango=b.1.575)). Accessed 30 June 2021.
- 206 12. Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Personalized Virology Initiative
207 study group, Krammer, F., Simon, V., Martinez-Sobrido, L., García-Sastre, A.,
208 Schotsaert, M. 2021. SARS-CoV-2 spike E484K mutation reduces antibody
209 neutralisation. *The Lancet. Microbe* 2:e283–e284. [https://doi.org/10.1016/S2666-](https://doi.org/10.1016/S2666-5247(21)00068-9)
210 [5247\(21\)00068-9](https://doi.org/10.1016/S2666-5247(21)00068-9).
- 211 13. Resende PC, Gräf T, Paixão ACD, Appolinario L, Lopes RS, Mendonça ACDF,
212 da Rocha ASB, Motta FC, Neto LGL, Khouri R, de Oliveira CI, Santos-
213 Muccillo P, Bezerra JF, Teixeira DLF, Riediger I, Debur MDC, Ribeiro-
214 Rodrigues R, Leite AB, do Santos CA, Gregianini TS, Fernandes SB, Bernardes
215 AFL, Cavalcanti AC, Miyajima F, Sachhi C, Mattos T, da Costa CF, Delatorre
216 E, Wallau GL, Naveca FG, Bello G, Siqueira MM.. 2021. A Potential SARS-
217 CoV-2 Variant of Interest (VOI) Harboring Mutation E484K in the Spike
218 Protein Was Identified within Lineage B.1.1.33 Circulating in Brazil. *Viruses*
219 13:724. <https://doi.org/10.3390/v13050724>.
- 220 14. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-
221 Babajew D, Cipolla M, Gaebler C, Lieberman JA, Oliveira TY, Yang Z,
222 Abernathy ME, Huey-Tubman KE, Hurley A, Turroja M, West KA, Gordon K,
223 Millard KG, Ramos V, Da Silva J, Xu J, Colbert RA, Patel R, Dizon J, Unson-
224 O'Brien C, Shimeliovich I, Gazumyan A, Caskey M, Bjorkman PJ, Casellas R,
225 Hatziioannou T, Bieniasz PD, Nussenzweig MC. 2021. mRNA vaccine-elicited

226 antibodies to SARS-CoV-2 and circulating variants. *Nature* 592:616–622.

227 <https://doi.org/10.1038/s41586-021-03324-6>.

228

229 **Figure 1.** Timeline of SARS-CoV-2 B.1.575, B1.575.1 and B.1.575.2 linages
230 emergence in Pamplona between January and June 2021.




Figure 1. Timeline of SARS-CoV-2 B.1.575, B1.575.1 and B.1.575.2 lineages emergence in Pamplona between January and June 2021.